Tirzepatide
LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
Every box carries a batch number. Look it up and you get the analytical data for the exact vials you received.
Batch lookup →LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
Retatrutide activates three receptors from one molecule: GLP-1, GIP and glucagon. The glucagon arm is what distinguishes it from dual agonists — it is proposed to add an energy-expenditure component on top of the appetite and gastric-emptying effects of GLP-1/GIP agonism. A 48-week phase 2 obesity study reported mean weight reductions of 22.8% and 24.2% at the 8 mg and 12 mg doses. Separate phase 2a work reported reductions in liver fat content in metabolic dysfunction-associated steatotic liver disease. Gastrointestinal events were the most frequently reported adverse effects across trials.
Prices in USD per sealed box of 10 vials. Bulk pricing available from 10 boxes — see wholesale.
| Vial strength | Box | Price | |
|---|---|---|---|
| 5mg | 10 vials |
$75
$7.50 per vial
|
Order 5mg |
| 10mg | 10 vials |
$118
$11.80 per vial
|
Order 10mg |
| 15mg | 10 vials |
$153
$15.30 per vial
|
Order 15mg |
| 20mg | 10 vials |
$168
$16.80 per vial
|
Order 20mg |
| 30mg | 10 vials |
$208
$20.80 per vial
|
Order 30mg |
| 50mg | 10 vials |
$333
$33.30 per vial
|
Order 50mg |
| 60mg | 10 vials |
$338
$33.80 per vial
|
Order 60mg |
Links open peer-reviewed sources on PubMed. These are provided so you can read the primary literature yourself. Citing a study is not a claim that this compound is safe or effective for any use in humans.
LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
TH9507, trans-3-hexenoyl-GHRH(1-44)
A stabilised GHRH(1-44) analog and the only GH-axis compound with regulatory approval specifically for reducing visceral adipose tissue.
A small-molecule NNMT inhibitor studied in adipocyte metabolism and NAD+ salvage research.
This website sells laboratory research chemicals. Everything on it is intended for qualified researchers and is not for human or veterinary consumption.
We are sorry — you must be at least 21 years old to view this site. Please close this window.
By entering you confirm you are at least 21 years of age, that you will use all products for laboratory research purposes only, and that you accept our Terms of Sale, Privacy Policy and Research Disclaimer.